Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has updated Kybella's labeling to warn of serious risks when the fat-dissolving injection is used outside its approved area under the chin. Reports linked off-label use to nerve injuries, vision problems, and long-lasting lumps at injection sites. Healthcare providers are urged to review prescribing guidelines before administering the treatment.
The FDA has approved updated labeling for Kybella (deoxycholic acid), the injectable treatment approved in 2015 for reducing submental fat — commonly known as a double chin. The new warnings flag serious risks when the drug is used outside its approved area, including neuromuscular injuries and persistent nodules or masses at injection sites that may require medical intervention.
The agency's decision followed a review of adverse event reports and medical literature, uncovering a pattern of harm tied to off-label use. Healthcare providers are now instructed to carefully review prescribing information before administering Kybella and to counsel patients on warning signs to watch for.
By the Numbers:
Why it matters: As cosmetic injectables grow in popularity, off-label use is increasingly common — and this update is a reminder that even well-established aesthetic treatments carry real risks when used beyond their approved indications. Clinicians and patients alike need to be aware of the boundaries of safe use.
